LEGN (Legend Biotech) Insider Ownership: 0.02 % (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEGN Legend Biotech Corp LEGN
71 GF Score
Price $19.88
GF Value $79.60
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Insider Ownership?

Legend Biotech LEGN -3.02% 71 Insider Ownership is 0.02 % as of Aug. 29, 2026. GuruFocus rates LEGN with a GF Score™ of 71/100 and a GF Value™ of $79.60 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Legend Biotech's insider ownership is 0.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Legend Biotech's Institutional Ownership is 52.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Legend Biotech's Float Percentage Of Total Shares Outstanding is 42.29%.

Legend Biotech Insider Ownership Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Insider Ownership Chart

Legend Biotech Historical Data

The historical data trend for Legend Biotech can be seen below:

2026-05-31 2026-06-30 2026-07-31
Insider Ownership 0.02 0.02 0.02
LEGN
71GF Score
Legend Biotech Corp LEGN
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.02 % mean?
Legend Biotech (LEGN) has a Insider Ownership of 0.02 % as of Aug. 29, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Insider Ownership too high?
Legend Biotech's current Insider Ownership is 0.02 %. Overall, Legend Biotech has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Insider Ownership compare to TNGX and ACAD?
Legend Biotech's Insider Ownership of 0.02 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Legend Biotech and its competitors. Legend Biotech's current Insider Ownership is 0.02 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Significantly Undervalued. The stock's GF Value™ is $79.60, compared to a current price of $19.88 — trading 75% below its estimated fair value. The current Insider Ownership is 0.02 %. Legend Biotech's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Insider Ownership is 0.02 % as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $19.88 is trading 75% below its estimated GF Value™ of $79.60. GuruFocus considers Legend Biotech to be Significantly Undervalued.

Key valuation signals for LEGN:

  • Insider Ownership: 0.02 %
  • GF Value™: $79.60 vs. price of $19.88 (75% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
71GF Score

Get the complete analysis for LEGN

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.88
Price
$79.60
GF Value